CD274 and melanoma: A different PD-L1 testing antibody was used in the Keynote006 trial [39], which employed the 22C3 clone (Dako) and compared the efficacy and safety of pembrolizumab (an anti-PD-1 antibody) and ipilimumab in patients with advanced melanoma.